Weave Communications Stock Discussion

$Weave Communications (WEAV.US)$ fell some 10% after hours Thursday as the company's forward guidance and word of the CFO's retirement overshadowed Q4 earnings and revenue beats for the customer-engagement-software maker.
WEAV shed 10.6% to $15.09 shortly before 5 p.m. ET despite reporting $0.03 in non-GAAP earnings per share on $54.2 million of revenues. That beat the $0.02 of adjusted EPS on $53.2 million t...

The attention of AI Medteck stocks are rapidly increasing.
Pelosi's new holdings have doubled $Tempus AI (TEM.US)$ value in just a few weeks, and $Firefly Neuroscience (AIFF.US)$'s inclusion in NVIDIA's Connect program has also caused its stock price to soar.
In addition, DeepSeek's rapid rise has boosted the AI application sector, particularly in medicine/healthcare. Cathie Wood believes medical AI is undervalued, with untapped pot...

The tech industry is constantly evolving, and small-cap stocks often present unique opportunities for investors seeking high growth potential. With the advent of 6G technology on the horizon, several small-cap tech companies are poised to make significant strides. Here are 11 tech small-cap stocks that are worth watching, along with a look at the promising future of AI, 6G, and the small-cap tech market.
1.   $MeridianLink (MLNK.US)$
MeridianLink provid...

$Weave Communications (WEAV.US)$
Gotta grab this one when it's a little more sold off

$Weave Communications (WEAV.US)$  this company not bad

On the last trading day, the NASDAQ Composite index rose0.52%, while the S&P 500 index climbed0.06%, and the Dow Jones Industrial Average dropped0.44%.
On Thursday, there was no traditional IPO filed and seven new stocks officially listed for trading.Biotech companyVaxxinity rose27.31% in first day of trading, valued at $2.08 billion.
Vaxxinity, founded in 2014,is aPhase 2 biotech company developing vaccine therapies for chronic diseases using synthetic peptides.
The company states synthetic peptide vaccine platform (“Vaxxine Platform”) has the potential to enable a new class of therapeutics that will improve the quality and convenience of care, reduce costs and increase access to treatments for a wide range of indications.
Its Vaxxine Platform is designed to harness the immune system to convert the body into its own “drug factory,” stimulating the production of antibodies with a therapeutic or protective effect.
Its current pipeline consists of five chronic disease product candidates from early to late-stage development across multiple therapeutic areas including Alzheimer’s Disease (“AD”), Parkinson’s Disease (“PD”), migraine and hypercholesterolemia.
Affirm Holdings, founded in 2012, offers "buy now pay later" loans for online purchases.
The company is building the next geneation platform for digital and mobile-first commerce.
The platform comprises three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. Our point-of-sale solution allows consumers to pay for purchases in fixed amounts without deferred interest, hidden fees, or penalties.
It went public in January 12th, 2021 and rose 98.45% in its market debut. As if November 11th, it has a market cap of $42.16 billion, with a listed-to-date return of 209.86%.
$Backblaze (BLZE.US)$ $Lulus Fashion Lounge (LVLU.US)$ $Vaxxinity (VAXX.US)$ $Weave Communications (WEAV.US)$ $Tivic Health Systems (TIVC.US)$ $HeartBeam (BEAT.US)$ $Winc (WBEV.US)$ $Affirm Holdings (AFRM.US)$